Retrospective Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 21, 2022; 28(39): 5750-5763
Published online Oct 21, 2022. doi: 10.3748/wjg.v28.i39.5750
Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival
Alexa R Weingarden, John Gubatan, Sundeep Singh, Tatiana Clorice Balabanis, Akshar Patel, Arpita Sharma, Aida Habtezion
Alexa R Weingarden, John Gubatan, Sundeep Singh, Tatiana Clorice Balabanis, Akshar Patel, Arpita Sharma, Aida Habtezion, Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, United States
Author contributions: Weingarden AR and Habtezion A designed the research study; Weingarden AR, Balabanis T, Patel A, and Sharma A performed data collection; Gubatan J analyzed data; Weingarden AR, Gubatan J, Singh S, and Habtezion A wrote and edited the manuscript; all authors have read and approve the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board at Stanford University (Approval No. IRB 57125).
Conflict-of-interest statement: None of the authors have any potential conflicts of interest to disclose.
Data sharing statement: Data availability upon request from authors.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Alexa R Weingarden, MD, PhD, Academic Fellow, Consultant Physician-Scientist, Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Alway Building, Room M211, 300 Pasteur Drive, Stanford, CA 94305, United States. aweingar@stanford.edu
Received: July 2, 2022
Peer-review started: July 2, 2022
First decision: August 1, 2022
Revised: September 24, 2022
Accepted: October 10, 2022
Article in press: October 10, 2022
Published online: October 21, 2022
Processing time: 107 Days and 14.2 Hours
Core Tip

Core Tip: Immune checkpoint inhibitor-mediated colitis (IMC) is a common adverse event following immune checkpoint inhibitor (ICI) therapy for cancer. We sought to determine the association of IMC with overall survival (OS) and progression-free survival (PFS) among cancer patients treated with ICI and identify clinical predictors of IMC. We performed a retrospective case-control study including 64 ICI users who developed IMC. In multivariate logistic regression analysis, IMC was significantly associated with a higher OS but not PFS. IMC was significantly associated with OS greater than 12 mo. Vitamin D supplementation was associated with increased risk of IMC.